February 7, 2025- Thermo Fisher Scientific Inc., announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry, addressing a critical unmet need for real-world, adolescent-specific evidence and data related to this autoimmune disease, which causes patchy or complete hair loss on the scalp and other areas of the body. Data collected will enable research to help better understand the burden of disease for AA patients, as well as the real-world effectiveness and safety of newly approved treatments.
The registry is now active in both the U.S. and Europe, with the first patient in North America enrolled in late 2024. This is the 12th independent registry from CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific. It complements an existing CorEvitas registry focused on AA in adults, launched in 2023.
The registry is designed to prospectively study alopecia areata, including the incidence of safety events of interest, medication utilization patterns and the comparative safety and effectiveness of treatments. It will also gather data on the history of AA in adolescents and the growth and development over time of adolescent AA patients undergoing treatment with new therapies.